Khapzory is owned by Acrotech Biopharma.
Khapzory contains Levoleucovorin.
Khapzory has a total of 1 drug patent out of which 0 drug patents have expired.
Khapzory was authorised for market use on 19 October, 2018.
Khapzory is available in powder;intravenous dosage forms.
The generics of Khapzory are possible to be released after 25 March, 2039.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11541012||ACROTECH BIOPHARMA||Compositions comprising disodium levofolinate|| |
(15 years from now)
Drugs and Companies using LEVOLEUCOVORIN ingredient
Market Authorisation Date: 19 October, 2018
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic